These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 36243011)

  • 1. Anti-IL 23 biologics for the treatment of plaque psoriasis.
    Vu A; Ulschmid C; Gordon KB
    Expert Opin Biol Ther; 2022 Dec; 22(12):1489-1502. PubMed ID: 36243011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review.
    Blauvelt A; Chiricozzi A; Ehst BD; Lebwohl MG
    Adv Ther; 2023 Aug; 40(8):3410-3433. PubMed ID: 37330926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A non-clinical comparative study of IL-23 antibodies in psoriasis.
    Zhou L; Wang Y; Wan Q; Wu F; Barbon J; Dunstan R; Gauld S; Konrad M; Leys L; McCarthy R; Namovic M; Nelson C; Overmeyer G; Perron D; Su Z; Wang L; Westmoreland S; Zhang J; Zhu R; Veldman G
    MAbs; 2021; 13(1):1964420. PubMed ID: 34460338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults.
    Boehncke WH; Brembilla NC; Nissen MJ
    Expert Rev Clin Immunol; 2021 Jan; 17(1):5-13. PubMed ID: 33251833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
    Li W; Ghamrawi R; Haidari W; Feldman SR
    Ann Pharmacother; 2020 Apr; 54(4):380-387. PubMed ID: 31672037
    [No Abstract]   [Full Text] [Related]  

  • 6. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
    Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologics for Psoriasis.
    Wride AM; Chen GF; Spaulding SL; Tkachenko E; Cohen JM
    Dermatol Clin; 2024 Jul; 42(3):339-355. PubMed ID: 38796266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
    Tausend W; Downing C; Tyring S
    J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
    J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
    Megna M; Tommasino N; Potestio L; Battista T; Ruggiero A; Noto M; Fabbrocini G; Genco L
    J Dermatolog Treat; 2022 Sep; 33(6):2813-2820. PubMed ID: 35603992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
    Yang K; Oak ASW; Elewski BE
    Am J Clin Dermatol; 2021 Mar; 22(2):173-192. PubMed ID: 33301128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for differential p19 targeting by IL-23 biologics.
    Daniele SG; Eldirany SA; Ho M; Bunick CG
    bioRxiv; 2023 Mar; ():. PubMed ID: 36945513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
    Ruggiero A; Fabbrocini G; Cinelli E; Ocampo Garza SS; Camela E; Megna M
    Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
    Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
    Sawyer LM; Malottki K; Sabry-Grant C; Yasmeen N; Wright E; Sohrt A; Borg E; Warren RB
    PLoS One; 2019; 14(8):e0220868. PubMed ID: 31412060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tildrakizumab for treating psoriasis.
    Galluzzo M; D'adamio S; Bianchi L; Talamonti M
    Expert Opin Biol Ther; 2017 May; 17(5):645-657. PubMed ID: 28271735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis.
    Haugh IM; Preston AK; Kivelevitch DN; Menter AM
    Drug Des Devel Ther; 2018; 12():3879-3883. PubMed ID: 30518998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12.
    Gottlieb AB; Saure D; Wilhelm S; Dossenbach M; Schuster C; Smith SD; Ramot Y; Thaçi D
    J Dermatolog Treat; 2022 Feb; 33(1):54-61. PubMed ID: 32299269
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.